Expanding resilient supply chains

Strong supply chains enable regular and predictable access to safe, quality-assured medical products, and resilient ones do so even during times of crisis. But increasingly, fragility in global pharmaceutical supply chains is causing shortages to occur more frequently and jeopardizing access to quality medical products. From improving visibility along the supply chain to expanding quality manufacturing to bring production closer to patients, we work to create resilient access to quality-assured medical products.

Localizing upstream production of key starting materials

Expanding production of medicines and medical products in low- and middle-income countries is important for sustainability, self-reliance, and health security. Specifically, increasing the strategic production of active pharmaceutical ingredients (APIs) and key starting materials (KSMs), employing advanced manufacturing technologies like continuous manufacturing, and facilitating technology transfer are critical to increasing production, reducing supply chain risks, and procuring medical products closer to patients.

Fostering enabling ecosystems to promote quality medicines

Strong health systems are critical to the pharmaceutical ecosystem and broader public health. Regional and national regulatory networks and authorities work together to advance harmonization; improve efficiencies; help people access safe, effective, and quality-assured medical products; and guard against harmful substandard and falsified products. Procuring quality products, strengthening drug safety monitoring to protect patients, and increasing private sector and country-led co-investments help create an enabling environment for increased production.